FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to a new peptide analog of acylated oxyntomodulin. The invention makes it possible to obtain a structural and functional analog of oxyntomodulin hormone, a sequence of which contains “cross-linking” of adjacent amino acid residues, the presence of which contributes to increasing the overall stability of a molecule of such an analog and, as a result, a longer half-life in vivo. The invention also makes it possible to obtain an analog of acylated oxyntomodulin, which is double agonist with the improved effect on GLP-1 and glucagon receptors compared to original native oxyntomodulin hormone.
EFFECT: peptides in accordance with the present invention can be used in the preparation of a pharmaceutical composition for the prevention or treatment of obesity or overweight or diabetes accompanied by obesity and overweight.
22 cl, 13 dwg, 16 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| LIQUID COMPOSITION | 2021 |
|
RU2838973C1 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| THERAPEUTIC USE OF GLUCAGON AND ITS COMBINATION | 2019 |
|
RU2838895C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
| MULTIAGONISTS AND THEIR APPLICATION | 2022 |
|
RU2833609C2 |
